1.50 USD
▲+0.07+2.04%
盘后 1.40 -4.90%
2026-08-03
市值
$6.10M
市盈率
—
EPS
-0.02
股息率
—
52 周区间
1.33 – 24.00
成交量
30.02K
Beta
-0.55
目标价
—
52W 低 1.3352W 高 24.00
价格走势
公司简介
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept...